

Obesity, Chronic Disease Risk Factors & Fighting Words – The Collateral Damage to Health

Jcg\ P\Ydg , GhYd\Ubm Puf_Yf UbX FYnU HU__U_

FÖ^]æ/c { ^}ç [-\Öè^c&•áæ) áhP ~c'fäç [}ÉÁW}äç^!•öc "á [-\CE! \æ) •æ•á- [íÁ T^ää&æ|ú&á^}&^•ÉÁ IHEFÁ YÉÁ Tæ! \@æ { ÁÚcÉÉÁŠšoc|ÁÚ [& \ÉÁCEÜÁ ÍGGE ÍÉÁWÜCE

GÖ^]æ/c { ^}ç [-\P ~c'fäç [}æ|ú&á^}&^•ÉÁU \æ@ [{ æÁÚcæc^ÁW}äç^!•öc "ÉÁÚcá||, æc^ÉÁUSÁ Í IÉ Í ÉÁWÜCE

HÖ^]æ/c { ^}ç [-\Ú^ääæç'á&•ÉÁW}äç^!•öc "á [-\CE! \æ) •æ•á- [íÁ T^ää&æ|ú&á^}&^•ÉÁ IHEFÁ YÉÁ Tæ! \@æ { ÁÚcÉÉÁŠšoc|ÁÚ [& \ÉÁCEÜÁ ÍGGE ÍÉÁWÜCE

'CE! \æ) •æ•áÖ@á|á^}ç [•]äçæ|ú^•^æç!&@ÁU) •öc "c^ÉÁFHÁÖ@á|á^}ç [•Á Yæ "ÉÁŠšoc|ÁÚ [& \ÉÁCEÜÁ ÍGGE GÉÁWÜCE

CcYgdcbX]b [Uih\cf:

homocysteine lowering group (mean baseline/post-trial plasma homocysteine levels of 11.5 & 9.3 micromoles, respectively) had a stroke when compared to patients in a group consuming a placebo (mean baseline/post-trial plasma homocysteine levels of 11.5 & 12.3 micromoles, respectively) [15]. In other words, the group being treated with a homocysteine lowering therapy accounted for approximately 43% of strokes experienced by participants, while the group being treated with a *placebo*